What is Rapid Micro Biosystems's accretion of end of term fee?

Rapid Micro Biosystems (RPID) reported accretion of end of term fee of $99K in Q1 2026.

Rapid Micro Biosystems RPID Accretion of end of term fee

Revenue$8.0M+11.1%

Gross profit$371.0K-8.2%

Operating income-$13.9M-18.8%

Net income-$14.3M-26.7%

EPS (diluted)-$0.31-19.2%

Cash & equivalents$14.1M-26.8%

Total debt$23.8M+301%

Total equity$20.4M-68.9%

Total assets$62.4M-27.0%

Operating cash flow-$15.1M-66.1%

CapEx$394.0K+23.5%

Free cash flow-$15.5M-64.7%

Market cap$86.19M-43.8%

Enterprise value$95.86M-31.7%

P/S2.5×-2.6×

Operating margin-144.2%-12.7pp

Net margin-145.8%-5.0pp

FCF margin-110.5%-14.9pp

Return on equity-116.7%-620pp

Debt / equity1.2×+1.1×

Current ratio2.6×-2.0×

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept rmb:LongTermDebtAccretion.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Rapid Micro Biosystems's accretion of end of term fee?: Rapid Micro Biosystems (RPID) reported accretion of end of term fee of $99K in Q1 2026.